Journal of Ocular Pharmacology and Therapeutics 2009-06-01

Comparison of efficacy of bromfenac sodium 0.1% ophthalmic solution and fluorometholone 0.02% ophthalmic suspension for the treatment of allergic conjunctivitis.

Hiroshi Fujishima, Kazumi Fukagawa, Yoji Takano, Mari Tanaka, Shigeki Okamoto, Dai Miyazaki, Jun Yamada, Atsuki Fukushima, Eiichi Uchio, Yayoi Nakagawa

Index: J. Ocul. Pharmacol. Ther. 25(3) , 265-70, (2009)

Full Text: HTML

Abstract

Bromfenac sodium (BF) 0.1% was compared with fluorometholone (FML) 0.02% for the treatment of seasonal allergic conjunctivitis when concomitantly used with disodium cromoglycate (DSCG) 2.0%.Eighty-six patients with seasonal allergic conjunctivitis were treated with DSCG four times a day, and BF was concomitantly administered twice a day in one eye and FML was administered four times a day in the contralateral eye for 1 week. Ocular signs were scored on a four-graded severity. Patients recorded symptoms using visual analog scale. Patients were asked which concomitant treatment was more suitable for them and scored global evaluation.All subjective symptom scores were decreased in both concomitant treatment groups compared with baseline (P < 0.05). Objective signs were significantly improved with the concomitant use of BF or FML with DSCG (P < 0.05). Neither symptoms nor signs differed significantly between the concomitant use of BF and FML. Fifteen patients selected BF and 29 patients selected FML as the more preferred concomitant eye drops, 42 patients judged no difference in efficacy between the groups. No significant difference was observed in patient's global evaluation between the groups.Bromfenac sodium for allergic conjunctivitis was effective, with efficacy equivalent to that of FML when used with DSCG.


Related Compounds

Related Articles:

Multiparametric assay using HepaRG cells for predicting drug-induced liver injury.

2015-07-02

[Toxicol. Lett. 236 , 16-24, (2015)]

Efficacy of ophthalmic nonsteroidal antiinflammatory drugs in suppressing anterior capsule contraction and secondary posterior capsule opacification.

2009-09-01

[J. Cataract Refract. Surg. 35(9) , 1614-8, (2009)]

Cyclooxygenase (COX)-inhibiting drug reduces HSV-1 reactivation in the mouse eye model.

2009-03-01

[Curr. Eye Res. 34(3) , 171-6, (2009)]

Aqueous prostaglandin E(2) of cataract patients at trough ketorolac and bromfenac levels after 2 days dosing.

2009-06-01

[Adv. Ther. 26(6) , 645-50, (2009)]

Acute corneal melt associated with topical bromfenac use.

2012-07-01

[Eye Contact Lens 38(4) , 260-2, (2012)]

More Articles...